Literature DB >> 27018968

Improving Surveillance for Surgical Site Infections Following Total Hip and Knee Arthroplasty Using Diagnosis and Procedure Codes in a Provincial Surveillance Network.

Alysha Rusk1, Kathryn Bush1, Marlene Brandt2, Christopher Smith3, Andrea Howatt1, Blanda Chow1, Elizabeth Henderson1.   

Abstract

OBJECTIVE To evaluate hospital administrative data to identify potential surgical site infections (SSIs) following primary elective total hip or knee arthroplasty. DESIGN Retrospective cohort study. SETTING All acute care facilities in Alberta, Canada. METHODS Diagnosis and procedure codes for 6 months following total hip or knee arthroplasty were used to identify potential SSI cases. Medical charts of patients with potential SSIs were reviewed by an infection control professional at the acute care facility where the patient was identified with a diagnosis or procedure code. For SSI decision, infection control professionals used the National Healthcare Safety Network SSI definition. The performance of traditional surveillance methods and administrative data-triggered medical chart review was assessed. RESULTS Of the 162 patients identified by diagnosis or procedure code, 46 (28%) were confirmed as an SSI by an infection control professional. More SSIs were identified following total hip vs total knee arthroplasty (42% vs16%). Of 46 confirmed SSI cases, 20 (43%) were identified at an acute care facility different than their procedure facility. Administrative data-triggered medical chart review with infection control professional confirmation resulted in a 1.1- to 1.7-fold increase in SSI rate compared with traditional surveillance. SSIs identified by administrative data resulted in sensitivity of 90% and specificity of 99%. CONCLUSION Medical chart review for cases identified through administrative data is an efficient supplemental SSI surveillance strategy. It improves case-finding by increasing SSI identification and making identification consistent across facilities, and in a provincial surveillance network it identifies SSIs presenting at nonprocedure facilities. Infect Control Hosp Epidemiol 2016;37:699-703.

Entities:  

Mesh:

Year:  2016        PMID: 27018968     DOI: 10.1017/ice.2016.53

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  Does body mass index affect the rate of adverse outcomes in total hip and knee arthroplasty? A retrospective review of a total joint replacement database

Authors:  Irfan Abdulla; Saboura Mahdavi; Hoa Khong; Richdeep Gill; James Powell; Kelly Dean Johnston; Rajrishi Sharma
Journal:  Can J Surg       Date:  2020-03-27       Impact factor: 2.089

2.  Divergences between healthcare-associated infection administrative data and active surveillance data in Canada.

Authors:  Virginie Boulanger; Étienne Poirier; Anne MacLaurin; Caroline Quach
Journal:  Can Commun Dis Rep       Date:  2022-01-26

3.  Association between Allogeneic Blood Transfusion and Wound Infection after Total Hip or Knee Arthroplasty: A Retrospective Case-Control Study.

Authors:  Ashish Taneja; Ahmed El-Bakoury; Hoa Khong; Pam Railton; Rajrishi Sharma; Kelly Dean Johnston; Shannon Puloski; Christopher Smith; James Powell
Journal:  J Bone Jt Infect       Date:  2019-04-20

4.  Assessment of risk factors for early-onset deep surgical site infection following primary total hip arthroplasty for osteoarthritis.

Authors:  Jonathan Bourget-Murray; Rohit Bansal; Alexandra Soroceanu; Sophie Piroozfar; Pam Railton; Kelly Johnston; Andrew Johnson; James Powell
Journal:  J Bone Jt Infect       Date:  2021-12-08

5.  Reliability and validity of multicentre surveillance of surgical site infections after colorectal surgery.

Authors:  Janneke D M Verberk; Stephanie M van Rooden; David J Hetem; Herman F Wunderink; Anne L M Vlek; Corianne Meijer; Eva A H van Ravensbergen; Elisabeth G W Huijskens; Saara J Vainio; Marc J M Bonten; Maaike S M van Mourik
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-21       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.